

Interactions with COVID-19 Adjunct Therapies

Charts updated 26 January 2022

Page 1 of 6

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	Aspirin	Dalteparin	Enoxaparin
Anaesthetics & Muscle Relaxants			
Alcuronium	◆	◆	◆
Bupivacaine	◆	◆	◆
Cisatracurium	◆	◆	◆
Desflurane	◆	◆	◆
Dexmedetomidine	◆	◆	◆
Enflurane	◆	◆	◆
Ephedrine	◆	◆	◆
Etidocaine	◆	◆	◆
Halothane	◆	◆	◆
Isoflurane	◆	◆	◆
Ketamine	◆	◆	◆
Nitrous oxide	◆	◆	◆
Propofol	◆	◆	◆
Rocuronium	◆	◆	◆
Sevoflurane	◆	◆	◆
Sufentanil	◆	◆	◆
Suxamethonium (succinylcholine)	◆	◆	◆
Tetracaine	◆	◆	◆
Thiopental	◆	◆	◆
Tizanidine	◆	◆	◆
Vecuronium	◆	◆	◆
Analgesics			
Alfentanil	◆	◆	◆
Aspirin	■	■	■
Buprenorphine	◆	◆	◆
Celecoxib	◆	■	■
Codeine	◆	◆	◆
Dextropropoxyphene	◆	◆	◆
Diamorphine (diacetylmorphine)	◆	◆	◆
Diclofenac	◆	■	■
Dihydrocodeine	◆	◆	◆
Fentanyl	◆	◆	◆
Hydrocodone	◆	◆	◆
Hydromorphone	◆	◆	◆
Ibuprofen	◆	■	■
Mefenamic acid	◆	■	■
Metamizole	■	◆	◆
Methadone	◆	◆	◆
Morphine	◆	◆	◆
Naproxen	◆	■	■
Nimesulide	◆	◆	◆
Oxycodone	◆	◆	◆
Paracetamol (Acetaminophen)	◆	◆	◆
Pethidine (Meperidine)	◆	◆	◆
Piroxicam	◆	■	■
Remifentanyl	◆	◆	◆
Tapentadol	◆	◆	◆
Tramadol	◆	◆	◆
Antiarrhythmics			
Amiodarone	◆	◆	◆
Bepidil	◆	◆	◆
Digoxin	◆	■	◆
Disopyramide	◆	◆	◆
Dofetilide	◆	◆	◆
Flecainide	◆	◆	◆
Lidocaine (Lignocaine)	◆	◆	◆
Mexiletine	◆	◆	◆
Propafenone	◆	◆	◆
Quinidine	◆	◆	◆

	Aspirin	Dalteparin	Enoxaparin
Antibacterials			
Amikacin	◆	◆	◆
Amoxicillin	◆	◆	◆
Ampicillin	◆	◆	◆
Bedaquiline	◆	◆	◆
Capreomycin	◆	◆	◆
Cefalexin	◆	◆	◆
Cefazolin	◆	◆	◆
Cefepime	◆	◆	◆
Cefixime	◆	◆	◆
Cefotaxime	◆	◆	◆
Ceftazidime	◆	◆	◆
Ceftriaxone	◆	◆	◆
Chloramphenicol	◆	◆	◆
Ciprofloxacin	◆	◆	◆
Clarithromycin	◆	◆	◆
Clavulanic acid	◆	◆	◆
Clindamycin	◆	◆	◆
Clofazimine	◆	◆	◆
Cloxacillin	◆	◆	◆
Cycloserine	◆	◆	◆
Dapsone	◆	◆	◆
Delamanid	◆	◆	◆
Doxycycline	◆	◆	◆
Ertapenem	◆	◆	◆
Erythromycin	◆	◆	◆
Ethambutol	◆	◆	◆
Ethionamide	◆	◆	◆
Flucloxacillin	◆	◆	◆
Gentamicin	◆	◆	◆
Imipenem/Cilastatin	◆	◆	◆
Isoniazid	◆	◆	◆
Kanamycin	◆	◆	◆
Levofloxacin	◆	◆	◆
Linezolid	◆	◆	◆
Meropenem	◆	◆	◆
Metronidazole	◆	◆	◆
Moxifloxacin	◆	◆	◆
Nitrofurantoin	◆	◆	◆
Ofloxacin	◆	◆	◆
Para-aminosalicylic acid	◆	◆	◆
Penicillins	◆	▲	◆
Piperacillin	◆	◆	◆
Pyrazinamide	◆	◆	◆
Rifabutin	◆	◆	◆
Rifampicin	◆	◆	◆
Rifapentine	◆	◆	◆
Rifaximin	◆	◆	◆
Spectinomycin	◆	◆	◆
Streptomycin	◆	◆	◆
Sulfadiazine	◆	◆	◆
Tazobactam	◆	◆	◆
Teliithromycin	◆	◆	◆
Tetracyclines	◆	■	◆
Tinidazole	◆	◆	◆
Trimethoprim/Sulfamethoxazole	◆	◆	◆
Vancomycin	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Interactions with COVID-19 Adjunct Therapies

Charts updated 26 January 2022

Page 2 of 6

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	Aspirin	Dalteparin	Enoxaparin
Anti-coagulant, Anti-platelet and Fibrinolytic			
Acenocoumarol	■	■	■
Apixaban	■	■	■
Argatroban	■	■	■
Aspirin (anti-platelet)	■	■	■
Betrixaban	■	■	■
Clopidogrel	■	■	■
Clopidogrel (recently stented patients)	■	■	■
Dabigatran	■	■	■
Dalteparin	■	■	■
Dipyridamole	■	■	■
Edoxaban	■	■	■
Enoxaparin	■	■	■
Fondaparinux	■	■	■
Heparin	■	■	■
Phenprocoumon	■	■	■
Prasugrel	■	■	■
Rivaroxaban	■	■	■
Streptokinase	■	■	■
Ticagrelor	■	■	■
Tinzaparin	■	■	■
Warfarin	■	■	■
Anticonvulsants			
Brivaracetam	◆	◆	◆
Carbamazepine	◆	◆	◆
Clonazepam	◆	◆	◆
Eslicarbazepine	◆	◆	◆
Ethosuximide	◆	◆	◆
Gabapentin	◆	◆	◆
Lacosamide	◆	◆	◆
Lamotrigine	◆	◆	◆
Levetiracetam	◆	◆	◆
Oxcarbazepine	◆	◆	◆
Perampanel	◆	◆	◆
Phenobarbital (Phenobarbitone)	◆	◆	◆
Phenytoin	▲	◆	◆
Pregabalin	◆	◆	◆
Primidone	◆	◆	◆
Retigabine	◆	◆	◆
Rufinamide	◆	◆	◆
Sultiame	◆	◆	◆
Tiagabine	◆	◆	◆
Topiramate	◆	◆	◆
Valproate (Divalproex)	▲	◆	◆
Vigabatrin	◆	◆	◆
Zonisamide	◆	◆	◆

	Aspirin	Dalteparin	Enoxaparin
Antidepressants			
Agomelatine	◆	◆	◆
Amitriptyline	◆	◆	◆
Bupropion	◆	◆	◆
Citalopram	◆	◆	◆
Clomipramine	◆	◆	◆
Desipramine	◆	◆	◆
Doxepin	◆	◆	◆
Duloxetine	◆	◆	◆
Escitalopram	◆	◆	◆
Fluoxetine	◆	◆	◆
Imipramine	◆	◆	◆
Lithium	◆	◆	◆
Maprotiline	◆	◆	◆
Mianserin	◆	◆	◆
Milnacipran	◆	◆	◆
Mirtazapine	◆	◆	◆
Nefazodone	◆	◆	◆
Nortriptyline	◆	◆	◆
Paroxetine	◆	◆	◆
Phenelzine	◆	◆	◆
Reboxetine	◆	◆	◆
Sertraline	◆	◆	◆
St John's wort	◆	◆	◆
Tranlycypromine	◆	◆	◆
Trazodone	◆	◆	◆
Trimipramine	◆	◆	◆
Venlafaxine	◆	◆	◆
Vortioxetine	◆	◆	◆
Anti-diabetics			
Acarbose	◆	◆	◆
Canagliflozin	◆	◆	◆
Dapagliflozin	◆	◆	◆
Dulaglutide	◆	◆	◆
Empagliflozin	◆	◆	◆
Exenatide	◆	◆	◆
Glibenclamide (Glyburide)	◆	◆	◆
Gliclazide	◆	◆	◆
Glimepiride	◆	◆	◆
Glipizide	◆	◆	◆
Insulin	◆	◆	◆
Linagliptin	◆	◆	◆
Liraglutide	◆	◆	◆
Metformin	◆	◆	◆
Nateglinide	◆	◆	◆
Pioglitazone	◆	◆	◆
Repaglinide	◆	◆	◆
Rosiglitazone	◆	◆	◆
Saxagliptin	◆	◆	◆
Sitagliptin	◆	◆	◆
Tolbutamide	◆	◆	◆
Vildagliptin	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Interactions with COVID-19 Adjunct Therapies

Charts updated 26 January 2022

Page 3 of 6

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	Aspirin	Dalteparin	Enoxaparin
Antifungals			
Amphotericin B	◆	◆	◆
Anidulafungin	◆	◆	◆
Caspofungin	◆	◆	◆
Fluconazole	◆	◆	◆
Flucytosine	◆	◆	◆
Griseofulvin	◆	◆	◆
Isavuconazole	◆	◆	◆
Itraconazole	◆	◆	◆
Ketoconazole	◆	◆	◆
Micafungin	◆	◆	◆
Miconazole	◆	◆	◆
Nystatin	◆	◆	◆
Posaconazole	◆	◆	◆
Terbinafine	◆	◆	◆
Voriconazole	◆	◆	◆
Antipsychotics/Neuroleptics			
Amisulpride	◆	◆	◆
Aripiprazole	◆	◆	◆
Asenapine	◆	◆	◆
Chlorpromazine	◆	◆	◆
Clozapine	◆	◆	◆
Fluphenazine	◆	◆	◆
Haloperidol	◆	◆	◆
Iloperidone	◆	◆	◆
Levomepromazine	◆	◆	◆
Olanzapine	◆	◆	◆
Paliperidone	◆	◆	◆
Perazine	◆	◆	◆
Periciazine	◆	◆	◆
Perphenazine	◆	◆	◆
Pimozide	◆	◆	◆
Pipotiazine	◆	◆	◆
Quetiapine	◆	◆	◆
Risperidone	◆	◆	◆
Sulpiride	◆	◆	◆
Thioridazine	◆	◆	◆
Tiapride	◆	◆	◆
Ziprasidone	◆	◆	◆
Zotepine	◆	◆	◆
Zuclopenthixol	◆	◆	◆

	Aspirin	Dalteparin	Enoxaparin
Anxiolytics/Hypnotics/Sedatives			
Alprazolam	◆	◆	◆
Bromazepam	◆	◆	◆
Buspirone	◆	◆	◆
Chlordiazepoxide	◆	◆	◆
Clobazam	◆	◆	◆
Clorazepate	◆	◆	◆
Diazepam	◆	◆	◆
Estazolam	◆	◆	◆
Flunitrazepam	◆	◆	◆
Flurazepam	◆	◆	◆
Hydroxyzine	◆	◆	◆
Lorazepam	◆	◆	◆
Lormetazepam	◆	◆	◆
Midazolam (oral)	◆	◆	◆
Midazolam (parenteral)	◆	◆	◆
Oxazepam	◆	◆	◆
Temazepam	◆	◆	◆
Triazolam	◆	◆	◆
Zaleplon	◆	◆	◆
Zolpidem	◆	◆	◆
Zopiclone	◆	◆	◆
Beta Blockers			
Atenolol	◆	◆	◆
Bisoprolol	◆	◆	◆
Carvedilol	◆	◆	◆
Metoprolol	◆	◆	◆
Nebivolol	◆	◆	◆
Oxprenolol	◆	◆	◆
Pindolol	◆	◆	◆
Propranolol	◆	◆	◆
Timolol	◆	◆	◆
Bronchodilators			
Acidinium bromide	◆	◆	◆
Aminophylline	◆	◆	◆
Formoterol	◆	◆	◆
Glycopyrronium bromide	◆	◆	◆
Indacaterol	◆	◆	◆
Ipratropium bromide	◆	◆	◆
Montelukast	◆	◆	◆
Olodaterol	◆	◆	◆
Roflumilast	◆	◆	◆
Salbutamol	◆	◆	◆
Salmeterol	◆	◆	◆
Theophylline	◆	◆	◆
Tiotropium bromide	◆	◆	◆
Umeclidinium bromide	◆	◆	◆
Vilanterol	◆	◆	◆
Calcium Channel Blockers			
Amlodipine	◆	◆	◆
Diltiazem	◆	◆	◆
Felodipine	◆	◆	◆
Nicardipine	◆	◆	◆
Nifedipine	◆	◆	◆
Nisoldipine	◆	◆	◆
Nitrendipine	◆	◆	◆
Verapamil	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

© Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Interactions with COVID-19 Adjunct Therapies

Charts updated 26 January 2022

Page 4 of 6

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	Aspirin	Dalteparin	Enoxaparin
Contraceptives/HRT			
Desogestrel (COC)	◆	◆	◆
Desogestrel (POP)	◆	◆	◆
Drospirenone (COC)	◆	◆	◆
Drospirenone (HRT)	◆	◆	◆
Dydrogesterone (HRT)	◆	◆	◆
Estradiol	◆	◆	◆
Ethinylestradiol	◆	◆	◆
Etonogestrel (implant)	◆	◆	◆
Etonogestrel (vaginal ring)	◆	◆	◆
Gestodene (COC)	◆	◆	◆
Levonorgestrel (COC)	◆	◆	◆
Levonorgestrel (emergency contrac.)	◆	◆	◆
Levonorgestrel (HRT)	◆	◆	◆
Levonorgestrel (implant)	◆	◆	◆
Levonorgestrel (IUD)	◆	◆	◆
Levonorgestrel (POP)	◆	◆	◆
Medroxyprogesterone (depot inj.)	◆	◆	◆
Medroxyprogesterone (oral)	◆	◆	◆
Norelgestromin (patch)	◆	◆	◆
Norethisterone (COC)	◆	◆	◆
Norethisterone (HRT)	◆	◆	◆
Norethisterone (IM depot)	◆	◆	◆
Norethisterone (POP)	◆	◆	◆
Norgestimate (COC)	◆	◆	◆
Norgestrel (COC)	◆	◆	◆
Norgestrel (HRT)	◆	◆	◆
Ulipristal	◆	◆	◆
Covid-19 Adjunct Therapies			
Aspirin (Covid-19 adjunct)	■	■	■
Dalteparin (Covid-19 adjunct)	■	■	■
Enoxaparin (Covid 19 adjunct)	■	■	■
Covid-19 Antiviral Therapies			
Azithromycin	◆	◆	◆
Bamlanivimab/Etesevimab	◆	◆	◆
Casirivimab/Imdevimab	◆	◆	◆
Chloroquine	◆	◆	◆
Favipiravir	◆	◆	◆
Hydroxychloroquine	◆	◆	◆
Interferon beta	◆	◆	◆
Ivermectin	◆	◆	◆
Molnupiravir	◆	◆	◆
Niclosamide	◆	◆	◆
Nirmatrelvir + ritonavir	◆	◆	◆
Nitazoxanide	◆	◆	◆
Remdesivir	◆	◆	◆
Ribavirin	◆	◆	◆
Sotrovimab	◆	◆	◆
Tixagevimab/Cilgavimab	◆	◆	◆

	Aspirin	Dalteparin	Enoxaparin
Covid-19 Host-directed Therapies			
Anakinra	◆	◆	◆
Baricitinib	◆	◆	◆
Budesonide (inhaled)	◆	◆	◆
Canakinumab	◆	◆	◆
Colchicine	◆	◆	◆
Covid 19 convalescent plasma	◆	◆	◆
Covid-19 vaccines	◆	◆	◆
Dexamethasone (low dose)	■	◆	◆
Fluvoxamine	◆	◆	◆
Hydrocortisone (oral or IV)	■	◆	◆
Infliximab	◆	◆	◆
Methylprednisolone (oral or IV)	■	◆	◆
Ruxolitinib	◆	◆	◆
Sarilumab	◆	◆	◆
Tocilizumab	◆	◆	◆
Gastrointestinal Agents			
Alosetron	◆	◆	◆
Antacids	◆	◆	◆
Bisacodyl	◆	◆	◆
Cimetidine	◆	◆	◆
Cisapride	◆	◆	◆
Esomeprazole	◆	◆	◆
Famotidine	◆	◆	◆
Lactulose	◆	◆	◆
Lansoprazole	◆	◆	◆
Loperamide	◆	◆	◆
Magnesium salts (oral)	◆	◆	◆
Mesalazine	◆	◆	◆
Omeprazole	◆	◆	◆
Pantoprazole	◆	◆	◆
Prucalopride	◆	◆	◆
Rabeprazole	◆	◆	◆
Ranitidine	◆	◆	◆
Senna	◆	◆	◆
Gastrointestinal Agents (anti-emetics)			
Aprepitant	◆	◆	◆
Cyclizine	◆	◆	◆
Dolasetron	◆	◆	◆
Domperidone	◆	◆	◆
Dronabinol	◆	◆	◆
Granisetron	◆	◆	◆
Metoclopramide	◆	◆	◆
Ondansetron	◆	◆	◆
Prochlorperazine	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Interactions with COVID-19 Adjunct Therapies

Charts updated 26 January 2022

Page 5 of 6

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	Aspirin	Dalteparin	Enoxaparin
HCV DAAs			
Elbasvir/Grazoprevir	◆	◆	◆
Glecaprevir/Pibrentasvir	◆	◆	◆
Ledipasvir/Sofosbuvir	◆	◆	◆
Ombitasvir/Paritaprevir/r	◆	◆	◆
Ombitasvir/Paritaprevir/r + Dasabuvir	◆	◆	◆
Sofosbuvir	◆	◆	◆
Sofosbuvir/Velpatasvir	◆	◆	◆
Sofosbuvir/Velpatasvir/Voxilaprevir	◆	◆	◆
HIV Antiretroviral Therapies			
Abacavir	◆	◆	◆
Albuvirtide	◆	◆	◆
Atazanavir alone	◆	◆	◆
Atazanavir + ritonavir	◆	◆	◆
Atazanavir/cobicistat	◆	◆	◆
Bictegravir/Emtricitabine/TAF	◆	◆	◆
Cabotegravir (oral)	◆	◆	◆
Cabotegravir/rilpivirine (long acting)	◆	◆	◆
Darunavir + ritonavir	◆	◆	◆
Darunavir/cobicistat	◆	◆	◆
Darunavir/Cobi/Emtricitabine/TAF	◆	◆	◆
Dolutegravir	◆	◆	◆
Dolutegravir/Lamivudine	◆	◆	◆
Dolutegravir/Rilpivirine	◆	◆	◆
Dolutegravir/Abacavir/Lamivudine	◆	◆	◆
Doravirine	◆	◆	◆
Doravirine/Lamivudine/Tenofovir-DF	◆	◆	◆
Efavirenz	◆	◆	◆
Elvitegravir/Cobi/Emtricitabine/TAF	◆	◆	◆
Elvitegravir/Cobi/Emtricitabine/TDF	◆	◆	◆
Emtricitabine	◆	◆	◆
Emtricitabine/Tenofovir alafenamide	◆	◆	◆
Emtricitabine/Tenofovir-DF	◆	◆	◆
Etravirine	◆	◆	◆
Fostemsavir	◆	◆	◆
Ibalizumab-uyk	◆	◆	◆
Lamivudine	◆	◆	◆
Lopinavir/ritonavir	◆	◆	◆
Maraviroc	◆	◆	◆
Nevirapine	◆	◆	◆
Raltegravir	◆	◆	◆
Rilpivirine	◆	◆	◆
Rilpivirine/Emtricitabine/TAF	◆	◆	◆
Rilpivirine/Emtricitabine/TDF	◆	◆	◆
Tenofovir-DF	◆	◆	◆
Zidovudine	◆	◆	◆

	Aspirin	Dalteparin	Enoxaparin
Hypertension / Heart Failure Agents			
Aliskiren	◆	◆	◆
Ambrisentan	◆	◆	◆
Amiloride	◆	■	■
Benazepril	◆	◆	◆
Bendroflumethiazide	◆	◆	◆
Bosentan	◆	◆	◆
Candesartan	◆	◆	◆
Captopril	◆	◆	◆
Chlortalidone	◆	◆	◆
Cilazapril	◆	◆	◆
Clonidine	◆	◆	◆
Dopamine	◆	◆	◆
Doxazosin	◆	◆	◆
Enalapril	◆	◆	◆
Eplerenone	◆	■	■
Epoprostenol	■	■	■
Eprosartan	◆	◆	◆
Fosinopril	◆	◆	◆
Furosemide	◆	◆	◆
Hydralazine	◆	◆	◆
Hydrochlorothiazide	◆	◆	◆
Iloprost	■	■	■
Indapamide	◆	◆	◆
Irbesartan	◆	◆	◆
Isosorbide dinitrate	◆	◆	◆
Ivabradine	◆	◆	◆
Labetalol	◆	◆	◆
Lacidipine	◆	◆	◆
Lercanidipine	◆	◆	◆
Lisinopril	◆	◆	◆
Losartan	◆	◆	◆
Macitentan	◆	◆	◆
Methyldopa	◆	◆	◆
Metolazone	◆	◆	◆
Moxonidine	◆	◆	◆
Olmesartan	◆	◆	◆
Perindopril	◆	◆	◆
Prazosin	◆	◆	◆
Quinapril	◆	◆	◆
Ramipril	◆	◆	◆
Ranolazine	◆	◆	◆
Riociguat	◆	◆	◆
Sacubitril	◆	◆	◆
Selexipag	◆	◆	◆
Sildenafil (PAH)	◆	◆	◆
Sodium nitroprusside	◆	◆	◆
Spironolactone	◆	■	■
Tadalafil (PAH)	◆	◆	◆
Telmisartan	◆	◆	◆
Terazosin	◆	◆	◆
Torasemide	◆	◆	◆
Trandolapril	◆	◆	◆
Treprostinil	■	■	■
Valsartan	◆	◆	◆
Xipamide	◆	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected

Interactions with COVID-19 Adjunct Therapies

Charts updated 26 January 2022

Page 6 of 6

Please check www.covid19-druginteractions.org for updates.

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers.

	Aspirin	Dalteparin	Enoxaparin
Immunosuppressants			
Adalimumab	◆	◆	◆
Anti-thymocyte globulin	◆	◆	◆
Azathioprine	◆	◆	◆
Basiliximab	◆	◆	◆
Belatacept	◆	◆	◆
Ciclosporin	◆	◆	◆
Everolimus	◆	◆	◆
Methotrexate	◆	◆	◆
Mycophenolate	◆	◆	◆
Pirfenidone	◆	◆	◆
Sirolimus	◆	◆	◆
Tacrolimus	◆	◆	◆
Inotropes & Vasopressors			
Adrenaline (Epinephrine)	◆	◆	◆
Dobutamine	◆	◆	◆
Noradrenaline	◆	◆	◆
Vasopressin	◆	◆	◆
Lipid Lowering Agents			
Atorvastatin	◆	◆	◆
Bezafibrate	◆	◆	◆
Clofibrate	◆	◆	◆
Evolocumab	◆	◆	◆
Ezetimibe	◆	◆	◆
Fenofibrate	◆	◆	◆
Fish oils	◆	◆	◆
Fluvastatin	◆	◆	◆
Gemfibrozil	◆	◆	◆
Lovastatin	◆	◆	◆
Pitavastatin	◆	◆	◆
Pravastatin	◆	◆	◆
Rosuvastatin	◆	◆	◆
Simvastatin	◆	◆	◆

	Aspirin	Dalteparin	Enoxaparin
Other			
Acetylcysteine	◆	◆	◆
Aciclovir	◆	◆	◆
Alendronic acid	◆	◆	◆
Alfuzosin	◆	◆	◆
Allopurinol	◆	◆	◆
Calcium supplements	◆	◆	◆
Carbocisteine	◆	◆	◆
Dextromethorphan	◆	◆	◆
Donepezil	◆	◆	◆
Eltrombopag	◆	◆	◆
Entecavir	◆	◆	◆
Finasteride	◆	◆	◆
Folic acid	◆	◆	◆
Guaifenesin	◆	◆	◆
Levodopa	◆	◆	◆
Levothyroxine	◆	◆	◆
Magnesium sulphate (IV)	◆	◆	◆
Melatonin	◆	◆	◆
Memantine	◆	◆	◆
Mirabegron	◆	◆	◆
Potassium	◆	◆	◆
Pramipexole	◆	◆	◆
Pyridostigmine	◆	◆	◆
Oseltamivir	◆	◆	◆
Tamsulosin	◆	◆	◆
Steroids			
Beclometasone	■	◆	◆
Betamethasone	■	◆	◆
Budesonide (oral/rectal)	■	◆	◆
Ciclesonide	◆	◆	◆
Clobetasol	◆	◆	◆
Fludrocortisone	■	◆	◆
Flunisolide	◆	◆	◆
Fluocinolone	◆	◆	◆
Fluticasone	◆	◆	◆
Hydrocortisone (topical)	◆	◆	◆
Megestrol acetate	◆	◆	◆
Methylprednisolone (topical)	◆	◆	◆
Mometasone	◆	◆	◆
Nandrolone	◆	◆	◆
Oxandrolone	◆	◆	◆
Prednisolone	■	◆	◆
Prednisone	■	◆	◆
Stanozolol	◆	◆	◆
Testosterone	◆	◆	◆
Triamcinolone	■	◆	◆

Key to symbols

●	These drugs should not be coadministered
■	Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
▲	Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
◆	No clinically significant interaction expected